Archive | March, 2014

Dr. Michael Har-Noy Discusses AlloStimTM Infusion in HIV-Infected Patients

7 Mar

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., a biotechnology company in Israel, says that regulatory T suppressor cells (Tregs) are active in HIV infection and tend to suppress cellular immunity.  He adds that Programmed cell death protein 1 (PD-1) and Cytotoxic T-lymphocyte antigen 4 (CTLA-4) are also up-regulated on HIV-specific CD4 T cells and that this expression correlates with an increase measured HIV.  Dr. Michael Har-Noy notes that intravenous AlloStimTM infusion shuts off Tregs that inhibit cellular immunity against various cancers and enables these cells to morph into non-suppressor types.  Dr. Michael Har-Noy believes that, in the face of AlloStimTM infusion, down regulation of PD-1 and CTLA-4, as well as Treg function reversal, might create an immune environment that would help a patient to clear the HIV.

Dr. Michael Har-Noy says that CD40 ligand (CD40L), a member of the tumor necrosis factor group of cell surface molecules, is expressed on viral particles and facilitates the activation of dendritic cells and macrophages.  This activation leads to increased activation of CD4+ T cells, thereby promoting the replication of latent HIV in these lymphocytes.  Dr. Michael Har-Noy indicates that intravenous AlloStimTM infusion greatly increases CD40L expression.  Since CD40L expression helps the immune system control viral replication by inducing HIV-suppressive chemokines and increasing the production of anti-HIV antibodies and cytotoxic T-cells, Dr. Michael Har-Noy concludes that AlloStimTM infusion may greatly enhance the ability of a patient’s immune system to suppress the HIV.

Lastly, Dr. Michael Har-Noy notes that natural killer (NK) cells are a vital part of a person’s innate immune response against viral infections. NK cell-mediated cytolytic activity is impaired in HIV-infected patients.  AlloStimTM infusion in cancer patients activates NK cells.  Therefore, Dr. Michael Har-Noy concludes that by enhancing NK cell function, AlloStimTM infusion may impose significant immunologic pressure on the HIV.

Dr. Michael Har-Noy is now conducting a Phase I/II study of AlloStimTM administration in HIV-infected patients.  This study is part of a broad Compassionate Use program and is being conducted in Bangkok, Thailand.  For more information, visit www.immunocare.net

Advertisements

Dr. Michael Har-Noy Discusses The Rationale Behind His Ground-Breaking CRCL-AlloVaxTM Treatment

4 Mar

Dr. Michael Har-Noy, CEO of the Israeli biotechnology company Immunovative Therapies Ltd., says that the CRCL-AlloVax™ anti-tumor vaccine is an immunologic treatment that has been designed based upon scientific principle and extensive research.  The potential benefit of this therapeutic vaccine has been previously demonstrated in extensive pre-clinical work and in early clinical trials.  Dr. Michael Har-Noy is currently conducting a Phase I/II study of CRCL-AlloVax™ in Bangkok, Thailand.  This study is part of a comprehensive Compassionate Use program.

It is well recognized, says Dr. Michael Har-Noy, that prior approaches to treating cancer with immunotherapy have demonstrated very limited efficacy.  CRCL-AlloVax™ represents an anti-tumor vaccine designed specifically with these previous failures in mind.  In developing CRCL-AlloVaxTM, Dr. Michael Har-Noy specifically considered the obstacles which have hindered the clinical efficacy of prior immunotherapy approaches and took measures to circumvent them.

Dr. Michael Har-Noy describes CRCL-AlloVaxTM as a vaccine engineered to elicit a response similar to the already proven and often curative tumor killing mechanism of an allogeneic bone marrow transplant.  Unfortunately, the allogeneic bone marrow transplant is frequently associated with the lethal side effect of graft-versus-host disease (GVHD).  The CRCL-AlloVax™ vaccine, says Dr. Michael Har-Noy, is designed to preserve the proven beneficial anti-tumor effect of a bone marrow transplant while eliminating the devastating GVHD side-effect.

The beneficial anti-tumor effect of an allogeneic bone marrow transplant, says Dr. Michael Har-Noy, has been shown to eradicate significant solid tumor burdens in patients with chemotherapy-resistant metastases. However, this phenomenon has no practical large-scale application due to the GVHD side effect.   Dr. Michael Har-Noy believes that the capacity of CRCL-AlloVax™ to provide patients with a proven anti-tumor immune effect without risk of GVHD is a landmark break-through in immunotherapy drug design.  The powerful scientific theory behind CRCL-AlloVaxTM and the early promising clinical results provides the rationale for this experimental compound to be available to metastatic cancer patients for early access.

Dr. Michael Har-Noy is currently running a preliminary Phase I/II study of CRCL-AlloVaxTM in patients with various types of chemotherapy and radiation-resistant metastatic cancer.  This study is part of a broad Compassionate Use program in Bangkok, Thailand.  For more information, please visit www.immunocare.net